Vivo Capital IX LLC 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 5:48 pm Sale | 2022-12-31 | 13G | Mereo BioPharma Group plc MREO | Vivo Capital IX LLC | 3,761,947 3.100% | -5,647,104 (-60.02%) | Filing |
| 2022-02-11 5:26 pm Purchase | 2021-12-31 | 13G | Mereo BioPharma Group plc MREO | Vivo Capital IX LLC | 9,409,051 7.800% | 448,755 (+5.01%) | Filing |
| 2021-02-16 4:30 pm Sale | 2020-12-31 | 13G | Mereo BioPharma Group plc MREO | Vivo Capital IX LLC | 8,960,296 8.168% | -21,635,328 (-70.71%) | Filing |
| 2020-07-10 4:30 pm Purchase | 2020-06-30 | 13G | Mereo BioPharma Group plc MREO | Vivo Capital IX LLC | 30,595,624 9.000% | 16,480,873 (+116.76%) | Filing |
| 2020-06-12 5:00 pm Purchase | 2020-06-04 | 13G | Mereo BioPharma Group plc MREO | Vivo Capital IX LLC | 14,114,751 6.600% | 14,114,751 (New Position) | Filing |